Michael Jain

53PUBLICATIONS
302CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (53)

|Jul 21, 2026
Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis.

|Jul 17, 2026
A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma.

|Jul 08, 2026
Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CART.

|Jun 20, 2026
Expanded antigen-specific donor regulatory T cells for GVHD prevention.

|Apr 15, 2026
Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders.

|Feb 11, 2026
Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies.

Rawan G Faramand, Zhuoer Xie, Michael D Jain

Pageof 9

Frequent Collaborators

16 joint publications

Frederick Locke

15 joint publications

Marco L Davila

12 joint publications

Taiga Nishihori

11 joint publications

Marion Subklewe